Dr Reddy's Laboratories Ltd
NSE:DRREDDY
Dr Reddy's Laboratories Ltd
Interest Income Expense
Dr Reddy's Laboratories Ltd
Interest Income Expense Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Interest Income Expense | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
|
Interest Income Expense
-₹2.6B
|
CAGR 3-Years
-151%
|
CAGR 5-Years
-36%
|
CAGR 10-Years
N/A
|
|
|
Cipla Ltd
NSE:CIPLA
|
Interest Income Expense
-₹655.8m
|
CAGR 3-Years
17%
|
CAGR 5-Years
19%
|
CAGR 10-Years
8%
|
|
|
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
|
Interest Income Expense
-₹3.2B
|
CAGR 3-Years
-32%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
4%
|
|
|
Lupin Ltd
NSE:LUPIN
|
Interest Income Expense
-₹3B
|
CAGR 3-Years
-48%
|
CAGR 5-Years
2%
|
CAGR 10-Years
-32%
|
|
|
T
|
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
|
Interest Income Expense
-₹2.8B
|
CAGR 3-Years
0%
|
CAGR 5-Years
10%
|
CAGR 10-Years
-6%
|
|
|
M
|
Mankind Pharma Ltd
NSE:MANKIND
|
Interest Income Expense
₹1.7B
|
CAGR 3-Years
21%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Dr Reddy's Laboratories Ltd
Glance View
In the bustling world of pharmaceuticals, Dr. Reddy's Laboratories Ltd. stands as a testament to innovation and resilience. Founded in 1984 by Dr. K. Anji Reddy, the company embarked on a journey to provide affordable and accessible medicine. Dr. Reddy's merged scientific rigor with a clear vision to eliminate health disparities worldwide. From creating complex generics and active pharmaceutical ingredients (APIs) to providing differentiated formulations, the company has built a strong foundation in both developed markets, like the United States and Europe, as well as in emerging markets such as India, Russia, and the CIS countries. This global footprint ensures that while many pharmaceutical companies are battling regulatory challenges and pricing pressures, Dr. Reddy's stays agile and competitive. The company's revenue streams primarily derive from its diverse portfolio of generic drugs, APIs, branded formulations, biologics, and proprietary products. Each sector is a strategic puzzle piece that enhances its market presence and ensures supply chain efficiency. Dr. Reddy's invests heavily in research and development to bolster its pipeline of future medications, aiming to address unmet medical needs and introduce value-added products. By leveraging strategic alliances and forging partnerships in development and distribution, the company adeptly navigates the complex landscape of the pharmaceutical industry, ensuring sustainable growth and reaffirming its commitment to affordable healthcare globally.
See Also
What is Dr Reddy's Laboratories Ltd's Interest Income Expense?
Interest Income Expense
-2.6B
INR
Based on the financial report for Dec 31, 2024, Dr Reddy's Laboratories Ltd's Interest Income Expense amounts to -2.6B INR.
What is Dr Reddy's Laboratories Ltd's Interest Income Expense growth rate?
Interest Income Expense CAGR 5Y
-36%
Over the last year, the Interest Income Expense growth was -100%. The average annual Interest Income Expense growth rates for Dr Reddy's Laboratories Ltd have been -151% over the past three years , -36% over the past five years .
You don't have any saved screeners yet